NP与GP方案治疗局部晚期非小细胞肺癌近期疗效观察  

Comparison of short-term efficacy between the NP and GP regimens in the treatment of locally advanced non-small cell lung cancer

作　　者：龚志敏[1] 陈怀云[1] 

机构地区：[1]华中科技大学同济医学院附属襄樊医院肿瘤科

出　　处：《现代肿瘤医学》2007年第7期932-934,共3页Journal of Modern Oncology

摘　　要：目的:观察长春瑞宾(NVB)与顺铂(DDP)组成的NP方案和吉西他滨(GEM)与顺铂(DDP)组成的GP方案对局部晚期非小细胞肺癌(NSCLC)的近期疗效和毒副作用。方法:将经病理组织学或细胞学证实的45例局部晚期NSCLC患者随机分为两组,A组(NP方案组)23例,B组(GP方案组)22例,分别给予NVB+DDP及GEM+DDP化疗,21天为一周期。结果:A组有效率为47.8%,B组有效率为54.5%,无统计学差异(P>0.05)。两组毒性反应均以骨髓抑制最为常见,消化道反应和静脉炎亦常见。Ⅲ～Ⅳ度白细胞减少发生率A组为34.8%,B组为31.8%;Ⅲ～Ⅳ度血小板减少发生率A组为4.3%,B组为9.1%。差异均无显著性(P>0.05)。静脉炎发生率A组为34.8%,B组为0,差异有显著性(P<0.05)。结论:NP方案和GP方案治疗NSCLC疗效相近,毒性反应均可耐受。Objective： To compare the short -term therapeutic efficacy ,toxicity and side reactions between navelbine plus cisplatin （NP regimen） and gemcitabine plus cisplatin （GP regimen ） in the treatment of locally advanced non - small cell lung cancer （ NSCLC ）. Methods ： Forty - five patients with cytologically and pathologically confirmed NSCLC were divided into two groups. Twenty - three cases in the A group received NP regimen chemotherapy. Twenty -two cases in the B group received GP regimen chemotherapy. Both regimens were repeated after a cycle of 21 days. Results ：Response rates were 47.8% （A group） and 54.5% （ B group） respectively for NP and GP regimens , without statistical difference between the two groups （ P 〉 0.05 ）. Myelosuppression was the major dose - limiting toxicity in both groups. Gastrointestinal reaction and local phlebitis were also observed. The rates of grade Ⅲ-Ⅳ leukopemia were 34.8% （ A group） and 31.8% （ B group ）, the rates of grade Ⅲ - Ⅳ thrombocytopenia were 4. 3% （A group） and 9.1% （B group） , without statistical difference between the two groups （P 〉 0.05 ）. Local rates of phlebitis were 34.8% （ A group） and 0 （ B group ）, with statistical difference between the two groups （ P 〈 0.05 ）. Conclusion ： The therapeutic effectiveness of NP regimen is similar to that of GP regimen. The toxic reactions were tolerable.

关 键 词：长春瑞宾 吉西他滨 顺铂 肺肿瘤 化学疗法 

分 类 号：R734.2[医药卫生—肿瘤]